These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 22101450)

  • 41. Clinical findings and survival time in dogs with advanced heart failure.
    Beaumier A; Rush JE; Yang VK; Freeman LM
    J Vet Intern Med; 2018 May; 32(3):944-950. PubMed ID: 29635788
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Effects of pimobendan on adverse cardiac events and physical activities in patients with mild to moderate chronic heart failure: the effects of pimobendan on chronic heart failure study (EPOCH study).
    Effects of Pimobendan on Chronic Heart Failure Study (EPOCH Study)
    Circ J; 2002 Feb; 66(2):149-57. PubMed ID: 11999639
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical efficacy of pimobendan (UD-CG 115 BS) in patients with chronic congestive heart failure.
    Baumann G; Ningel K; Permanetter B
    J Cardiovasc Pharmacol; 1989; 14 Suppl 2():S23-30. PubMed ID: 2478788
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease: a prospective, controlled, blinded and randomized study".
    Le Bobinnec G
    J Vet Intern Med; 2008; 22(2):243-4; author reply 245-6. PubMed ID: 18371019
    [No Abstract]   [Full Text] [Related]  

  • 45. Effects of pimobendan on exercise tolerance and quality of life in patients with heart failure.
    Kubo SH
    Cardiology; 1997; 88 Suppl 2():21-7. PubMed ID: 9142432
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pimobendan. A review of its pharmacology and therapeutic potential in congestive heart failure.
    Fitton A; Brogden RN
    Drugs Aging; 1994 May; 4(5):417-41. PubMed ID: 8043944
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Beneficial effects of pimobendan on exercise tolerance and quality of life in patients with heart failure. Results of a multicenter trial. The Pimobendan Multicenter Research Group.
    Kubo SH; Gollub S; Bourge R; Rahko P; Cobb F; Jessup M; Brozena S; Brodsky M; Kirlin P; Shanes J
    Circulation; 1992 Mar; 85(3):942-9. PubMed ID: 1537130
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Calcium sensitising agents in heart failure.
    Mathew L; Katz SD
    Drugs Aging; 1998 Mar; 12(3):191-204. PubMed ID: 9534020
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Milrinone. A clinical trial in 29 dogs with moderate to severe congestive heart failure.
    Keister DM; Kittleson MD; Bonagura JD; Pipers FS; Knauer KW
    J Vet Intern Med; 1990; 4(2):79-86. PubMed ID: 2187984
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Clinical efficacy and safety of pimobendan in treatment of heart failure--experience in Japan.
    Kato K
    Cardiology; 1997; 88 Suppl 2():28-36. PubMed ID: 9142433
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concerns about "Comparative adverse cardiac effects of pimobendan and benazepril monotherapy in dogs with mild degenerative mitral valve disease".
    Corcoran B; Culshaw G; Dukes-McEwan J; French A; Smith S; Swift S
    J Vet Intern Med; 2008; 22(2):243; author reply 245. PubMed ID: 18371020
    [No Abstract]   [Full Text] [Related]  

  • 52. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Improvement of cardiac performance by pimobendan, a new cardiotonic drug, in the experimental failing dog heart.
    Satoh K; Satoh Y; Imagawa J; Taira N
    Jpn Heart J; 1993 Mar; 34(2):213-9. PubMed ID: 8315818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Retrospective evaluation of the safety and tolerability of pimobendan in cats with obstructive vs nonobstructive cardiomyopathy.
    Ward JL; Kussin EZ; Tropf MA; Tou SP; DeFrancesco TC; Keene BW
    J Vet Intern Med; 2020 Nov; 34(6):2211-2222. PubMed ID: 33026124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Inotropic agents with calcium-sensitizing properties: clinical and hemodynamic effects of pimobendan.
    Kubo SH
    Coron Artery Dis; 1994 Feb; 5(2):119-26. PubMed ID: 8180743
    [No Abstract]   [Full Text] [Related]  

  • 56. Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.
    Wess G; Kresken JG; Wendt R; Gaugele J; Killich M; Keller L; Simak J; Holler P; Bauer A; Küchenhof H; Glaus T
    J Vet Intern Med; 2020 Nov; 34(6):2232-2241. PubMed ID: 32945575
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effect of pimobendan on exercise capacity in patients with heart failure: main results from the Pimobendan in Congestive Heart Failure (PICO) trial.
    Lubsen J; Just H; Hjalmarsson AC; La Framboise D; Remme WJ; Heinrich-Nols J; Dumont JM; Seed P
    Heart; 1996 Sep; 76(3):223-31. PubMed ID: 8868980
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension.
    Morita T; Nakamura K; Osuga T; Kawamoto S; Miki S; Sasaoka K; Takiguchi M
    J Vet Cardiol; 2020 Dec; 32():16-27. PubMed ID: 33080489
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A QUEST begins.
    Oyama MA
    J Vet Intern Med; 2008; 22(5):1076-8. PubMed ID: 18844829
    [No Abstract]   [Full Text] [Related]  

  • 60. Efficacy of inotropic support of the failing heart.
    Knight DH
    Vet Clin North Am Small Anim Pract; 1991 Sep; 21(5):879-904. PubMed ID: 1949498
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.